ACM
BOLT icon

ADAR1 Capital Management’s Bolt Biotherapeutics BOLT Stock Holding History

ADAR1 Capital Management’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,823
Closed -$62.4K – 226
2025
Q2 		$62.4K Sell
10,823
-1,425
-12% -$9.43K 0.01% 187
2025
Q1 		$98K Hold
12,248
– – 0.02% 167
2024
Q4 		$131K Hold
12,248
– – 0.03% 173
2024
Q3 		$159K Buy
12,248
+2,948
+32% +$40.6K 0.03% 172
2024
Q2 		$139K Buy
9,300
+9,050
+3,620% +$179K 0.03% 159
2024
Q1 		$7K Buy
+250
New +$5.79K ﹤0.01% 235

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ADAR1 Capital Management's BOLT Position: Q3 2025 in Review

ADAR1 Capital Management sold out of Bolt Biotherapeutics (BOLT) in Q3 2025, closing a stake of 10,823 shares — an estimated $62.4K sold.

ADAR1 Capital Management first reported a position in BOLT in Q1 2024 and held it in 6 quarters. The position peaked at $159K in Q3 2024. 24 funds tracked by Wall St. Rank hold BOLT as of Q3 2025.

  • ADAR1 Capital Management reported no remaining Bolt Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • ADAR1 Capital Management sold 10,823 Bolt Biotherapeutics shares in Q3 2025, an estimated $62.4K.
  • ADAR1 Capital Management first reported a position in Bolt Biotherapeutics in Q1 2024 and held it in 6 quarters.
  • ADAR1 Capital Management's Bolt Biotherapeutics position peaked at $159K in Q3 2024.
  • 24 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q3 2025.

Based on ADAR1 Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.